Who
John G. Houston
Director
Company insider
Files Form 4 as: Director, NextCure; President and CEO, Arvinas.
In numbers
- Trades disclosed
- 89
- Buys
- 1
- Sells
- 12
- Bought
- $480K
- Sold
- $18.2M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 26 Sep 2018
- Last trade
- 18 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 22 Jun 2026 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,340 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,340 at $0.00 | filing |
| 27 Feb 2026filed 2 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $62K4,688 at $13.24 | filing |
| 27 Feb 2026filed 2 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $249K18,822 at $13.24 | filing |
| 27 Feb 2026filed 2 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $155K11,787 at $13.14 | filing |
| 27 Feb 2026filed 2 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $62K4,688 at $13.24 | filing |
| 27 Feb 2026filed 2 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $249K18,822 at $13.24 | filing |
| 27 Feb 2026filed 2 Mar 2026 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $155K11,787 at $13.14 | filing |
| 20 Jun 2025filed 24 Jun 2025 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,700 at $0.00 | filing |
| 24 Feb 2025filed 25 Feb 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $439K26,184 at $16.75 | filing |
| 24 Feb 2025filed 25 Feb 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $85K5,154 at $16.55 | filing |
| 13 Feb 2025filed 18 Feb 2025 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —232,000 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —152,000 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,700 at $0.00 | filing |
| 23 Feb 2024filed 27 Feb 2024 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code A | —184,200 at $0.00 | filing |
| 23 Feb 2024filed 27 Feb 2024 | ARVN ArvinasBiotechnology | SEC FORM 4 Code A | —124,450 at $0.00 | filing |
| 23 Feb 2024filed 27 Feb 2024 | ARVN ArvinasBiotechnology | SEC FORM 4 Sold | $244K5,196 at $47.05 | filing |
| 22 Jun 2023filed 23 Jun 2023 | NXTC NextCureoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,250 at $0.00 | filing |
| 1 Mar 2023filed 3 Mar 2023 | ARVN Arvinasoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,510 at $0.00 | filing |
| 1 Mar 2023filed 3 Mar 2023 | ARVN ArvinasBiotechnology | SEC FORM 4 Code M | —17,510 | filing |
News
Financial Comparison: Arvinas (NASDAQ:ARVN) & Geron (NASDAQ:GERN)ARVN · tickerreport.com · 20 Oct 2026
0 headlines in the last 90 days name John G. Houston; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.